[Top][All Lists]

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[dev-serveez] Do it right now do not miss this great opportunity! Fresh

From: Aron Burnette
Subject: [dev-serveez] Do it right now do not miss this great opportunity! Fresh news
Date: Mon, 22 Jan 2007 21:30:21 -0060


Get Human BIOSYSTEMS INC. (HBSC.OB) stock today morning.     
Monday will be the day when your gains will be really RISE.     
It's getting growth almost every hour! So you can triple your balance any time. 
We are sure thet you had not opportunity like that before.  
Friday price: JAN 18 - $0.08    
On monday 22 January it will - 0.13$ at least and 0.20$ at most (not bad for a 
Inform your brokers in order they buy it immediately. 
Do not lose your chance.MORE THAN 35% EVERY DAY!  
HBSC just released this news.

U.S. Patent Office to Grant Human BioSystems its Fifth Patent, "Compositions, 
Methods and Apparatuses for Preserving Platelets"
Monday January 22, 7:00 am ET

PALO ALTO, CALIFORNIA--(MARKET WIRE)--Jan 22, 2007 -- Human BioSystems (HBS) 
(OTC BB:HBSC.OB - News), developer of preservation platforms for organs, blood 
platelets and other biomaterials, announced today that the U.S. Patent Office 
has allowed HBS' patent application for platelet preservation entitled 
"Compositions, Methods and Apparatuses for Preserving Platelets." A patent 
number is expected to be issued in the near future.

HBS has been granted four previous patents related to organ, platelet and 
biological material preservation. Including the patent to be issued, HBS' 
patent portfolio is as follows:

1. Methods and Apparatus for Preserving Biological Materials - U.S. Patent # 
2. Methods and Apparatuses for Preserving Platelets - U.S. Patent # 6,828,090
3. Methods and Solutions for Storing Donor Organs - U.S. Patent # 7,029,839
4. Preservation of Blood Platelets with Citrate - U.S. Patent # 7,083,910
5. Compositions, Methods and Apparatuses for Preserving Platelets - U.S. Patent 
number to be issued

"All of the patents we have received thus far serve to strengthen our 
intellectual property protection as we progress toward commercializing our 
technologies and bringing them to market," explained Dr. David Winter, 
President of Human BioSystems.

The latest patent to be awarded is among four patents that relate to the 
preservation of blood platelets, a blood component critical to cancer patients 
that have undergone chemotherapy/radiation treatments. Platelet infusions are 
necessary for a period of time following such cancer treatments to maintain 
adequate platelet counts. The lack of platelets could increase the chances of 

"HBS hopes to extend the preservation time of platelets beyond current 
standards while maintaining quality and safety by utilizing patented cooling 
methods not achieved by others thus far in the commercial blood banking 
industry. If successful, this could result in hundreds of millions of dollars 
in savings to blood centers and hospitals worldwide," concluded Dr. Winter.

HBS is headquartered in Palo Alto, California with research facilities in 

Certain statements contained herein are "forward-looking'' statements (as such 
term is defined in the Private Securities Litigation Reform Act of 1995). 
Because such statements include risks and uncertainties, actual results may 
differ materially from those expressed or implied by such forward-looking 
statements. Factors that could cause results to differ materially from those 
expressed or implied by such forward-looking statements include, but are not 
limited to, results from ongoing research and development as well as clinical 
studies, failure to obtain regulatory approval for the Company's products, if 
required, failure to develop a product based on the Company's technology, 
failure of any such products to compete effectively with existing products, the 
inability to find a strategic partner or to consummate a relationship with a 
potential strategic partner on acceptable terms, the effectiveness of 
protection of the Company's intellectual property, and other factors discussed 
in filings made by the Company with the Securities and Exchange Commission.


reply via email to

[Prev in Thread] Current Thread [Next in Thread]